Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
U.K.'s MRC Signs Pact With Genentech
by Lisa M. Jarvis
July 19, 2010
| A version of this story appeared in
Volume 88, Issue 29
MRC Technology, the commercialization agent for the U.K. Medical Research Council, has licensed to Genentech several small-molecule drug candidates for the treatment of neurological diseases. MRC gets an up-front payment and could receive milestones as compound development progresses. The Genentech deal is the first major small-molecule pact to emerge from MRC Technology’s year-old Center for Therapeutics Discovery. And the deal is MRC’s second with industry this month: AstraZeneca and MRC recently agreed to screen their combined compound libraries against 10 biological targets (C&EN, July 12, page 20).
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter